数字农科院2.0

DNA Subunit Vaccine and Recombinant BCG Based on Mycobacterial Lipoprotein LprO Enhance Anti-Tuberculosis Protection in the Lungs of Mice

文献类型： 外文期刊

作者： Huang, Weili;Xu, Shuqin;Shen, Lifang;Chen, Dan;Liu, Hanmei;Tang, Yuting;Liu, Xiaolin;Xiao, Wenxuan;Zhou, Ziwei;Zhang, Shifeng;Li, Jixi;Fan, Xiaoyong;Chu, Yuefeng;Zhang, Lu

作者机构：

关键词： tuberculosis;lipoprotein antigens;rBCG-lprO;DNA-lprO vaccine

期刊名称： VACCINES

ISSN：

年卷期： 2025 年 13 卷 4 期

页码：

收录情况： SCIE（2025版）

摘要： Background/Objectives: Over the past two centuries, tuberculosis (TB) has been responsible for approximately one billion deaths and continues to represent a significant global health challenge. Despite extensive research efforts, fully effective strategies for the prevention or eradication of TB remain elusive, highlighting the urgent demand for novel vaccines with enhanced safety profiles and efficacy. Lipoproteins, integral surface proteins of mycobacteria, are frequently associated with virulence and display notable immunogenicity, rendering them promising candidates for vaccine development. This study investigates the potential of the mycobacterial lipoprotein, LprO, as a vaccine antigen against TB. Methods: A pcDNA-lprO DNA vaccine was constructed, and its immunogenicity was evaluated using a murine model. Its protective efficacy was further assessed using a Mycobacterium marinum (M. marinum)-infected zebrafish model. Additionally, a recombinant BCG vaccine strain, BCG Japan::pNBV1-lprO, was generated. Its immunogenicity was tested in mice, and its safety was evaluated in SCID mice. Both vaccine candidates were further assessed in regard to their protective efficacy in a murine Mycobacterium tuberculosis (M. tb) infection model. Results: The pcDNA-lprO vaccine increased the M. tb-specific IFN-gamma-secreting lymphocytes in murine spleens and prolonged the survival of zebrafish infected with M. marinum. The recombinant BCG Japan::pNBV1-lprO vaccine elicited M. tb-specific Th1-type immune responses in mice compared to the standard BCG Japan strain. Both vaccines effectively reduced the bacterial burden of M. tb in murine lungs, offering superior protection relative to the control groups. Conclusions: These findings establish LprO as a compelling candidate for TB vaccine development, with both LprO-based DNA and recombinant BCG vaccines demonstrating robust protective effects against TB.

分类号：

  • 相关文献

[1]牛结核病. 刘思国,宫强,王牟平,王春来,彭永刚. 2004

[2]A Recombinase Polymerase Amplification-Coupled Cas12a Mutant-Based Module for Efficient Detection of Streptomycin-Resistant Mutations in Mycobacterium tuberculosis. Peng Liu,Xinjie Wang,Juan Liang,Qian Dong,Jinping Zhang,Dongxin Liu,Shuai Wang,Jing Bi,Wenqi Liu,Zhaoqin Wang,Liang Chen,Lei Liu,Xingxu Huang,Guoliang Zhang. 2022

[3]Optimizing antigen selection for the development of tuberculosis vaccines. Yang Yang,Yi Zhen Chen,Tian Xia. 2024

[4]Isolation and characterization of a protective monoclonal antibody targeting outer membrane protein (OmpA) against tuberculosis. Li, Huoming,Ji, Jiahong,Qu, Mengjin,Ma, Xiuling,Zuo, You,Tang, Minghui,Zeng, Lingyuan,Li, Hao. 2025

作者其他论文 更多>>